Prostate-specific antigen screening, a procedure designed to detect prostate cancer, recently received a failing grade from the U.S. Preventive Services Task Force. That report has weighed on Intuitive Surgical's (Nasdaq: ISRG ) growth, because PSA screenings have been a large driver of prostatectomies, one of the company's flagship procedures. In this video, Motley Fool health care analyst Brenton Flynn dives into the impact this trend is having on the company and where it might find growth in other areas.
Intuitive Surgical is disruptive innovator that has shown it is able to constantly reinvent itself as it adds new surgical procedures to its repertoire. A true renegade in the health care industry, the company rebelled against the status quo to lead a revolution in medical robotics. Early investors experienced unimaginable gains, some making as much as 30 times their initial investment. Even with those enormous gains in the rearview mirror, the stock could have plenty of room to run into the future. In a brand new premium report on Intuitive Surgical, we've commissioned Karl Thiel to outline the company's key opportunities and risks with surgical precision. As one of the minds behind our Rule Breakers recommendation of the stock in 2005 (before it went on to gain more than 1,000%) Thiel knows the Intuitive Surgical story inside and out. It's a must-read for any current or prospective investor, and comes loaded with a full year of analyst updates. Make sure to claim your copy today by clicking here now.